FYERS
Home
/
Stocks
/
Profit Loss
/
Astrazeneca Pharma India Profit & Loss

Astrazeneca Pharma India Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Mar 2018Dec 2017Sep 2017Jun 2017Mar 2017Dec 2016Sep 2016Jun 2016Mar 2016Dec 2015Sep 2015Jun 2015Mar 2015Dec 2014Sep 2014Jun 2014Mar 2014Dec 2013Sep 2013Jun 2013Mar 2013Dec 2012Sep 2012
₹683 Cr₹579 Cr₹612 Cr₹559 Cr₹526 Cr₹480 Cr₹440 Cr₹408 Cr₹388 Cr₹383 Cr₹306 Cr₹311 Cr₹295 Cr₹285 Cr₹250 Cr₹236 Cr₹232 Cr₹232 Cr₹201 Cr₹198 Cr₹175 Cr₹210 Cr₹200 Cr₹209 Cr₹194 Cr₹195 Cr₹224 Cr₹208 Cr₹205 Cr₹190 Cr₹215 Cr₹161 Cr₹161 Cr₹151 Cr₹129 Cr₹164 Cr₹128 Cr₹117 Cr₹152 Cr₹139 Cr₹141 Cr₹159 Cr₹145 Cr₹128 Cr₹132 Cr₹169 Cr₹108 Cr₹115 Cr₹126 Cr₹114 Cr₹119 Cr₹116 Cr₹125 Cr₹95 Cr₹105 Cr₹99 Cr
₹9 Cr₹6 Cr₹5 Cr₹6 Cr₹11 Cr₹16 Cr₹8 Cr₹8 Cr₹8 Cr₹9 Cr₹10 Cr₹8 Cr₹8 Cr₹8 Cr₹7 Cr₹7 Cr₹4 Cr₹4 Cr₹5 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹5 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹6 Cr₹3 Cr₹3 Cr₹3 Cr₹2 Cr₹3 Cr₹2 Cr₹5 Cr₹99 L₹10 Cr₹2 Cr₹2 Cr₹2 Cr₹1 Cr₹1 Cr₹2 Cr₹1 Cr₹1 Cr₹2 Cr₹2 Cr₹1 Cr₹2 Cr₹3 Cr₹3 Cr₹67 L₹22 L₹2 Cr
₹692 Cr₹585 Cr₹617 Cr₹565 Cr₹538 Cr₹497 Cr₹448 Cr₹416 Cr₹396 Cr₹392 Cr₹315 Cr₹319 Cr₹304 Cr₹293 Cr₹257 Cr₹243 Cr₹236 Cr₹236 Cr₹206 Cr₹201 Cr₹178 Cr₹213 Cr₹203 Cr₹214 Cr₹196 Cr₹198 Cr₹227 Cr₹212 Cr₹208 Cr₹196 Cr₹219 Cr₹165 Cr₹165 Cr₹153 Cr₹131 Cr₹167 Cr₹133 Cr₹118 Cr₹161 Cr₹141 Cr₹142 Cr₹161 Cr₹146 Cr₹130 Cr₹134 Cr₹170 Cr₹109 Cr₹116 Cr₹127 Cr₹116 Cr₹121 Cr₹119 Cr₹128 Cr₹96 Cr₹105 Cr₹101 Cr
₹639 Cr₹523 Cr₹571 Cr₹486 Cr₹462 Cr₹412 Cr₹372 Cr₹365 Cr₹353 Cr₹338 Cr₹294 Cr₹262 Cr₹232 Cr₹229 Cr₹217 Cr₹199 Cr₹209 Cr₹198 Cr₹189 Cr₹184 Cr₹165 Cr₹176 Cr₹175 Cr₹178 Cr₹170 Cr₹185 Cr₹192 Cr₹180 Cr₹174 Cr₹188 Cr₹178 Cr₹150 Cr₹156 Cr₹139 Cr₹143 Cr₹132 Cr₹126 Cr₹120 Cr₹140 Cr₹140 Cr₹127 Cr₹160 Cr₹137 Cr₹137 Cr₹131 Cr₹132 Cr₹123 Cr₹144 Cr₹145 Cr₹132 Cr₹119 Cr₹120 Cr₹126 Cr₹114 Cr₹123 Cr₹122 Cr
₹58 Cr₹67 Cr₹50 Cr₹81 Cr₹92 Cr₹103 Cr₹85 Cr₹61 Cr₹46 Cr₹58 Cr₹25 Cr₹61 Cr₹75 Cr₹68 Cr₹44 Cr₹48 Cr₹32 Cr₹42 Cr₹20 Cr₹21 Cr₹19 Cr₹43 Cr₹34 Cr₹40 Cr₹31 Cr₹18 Cr₹40 Cr₹37 Cr₹39 Cr₹12 Cr₹44 Cr₹18 Cr₹13 Cr₹18 Cr-₹8 Cr₹38 Cr₹11 Cr₹2 Cr₹25 Cr₹5 Cr₹20 Cr₹5 Cr₹13 Cr-₹2 Cr₹7 Cr₹42 Cr-₹9 Cr-₹25 Cr-₹14 Cr-₹13 Cr₹5 Cr₹2 Cr₹4 Cr-₹13 Cr-₹15 Cr-₹18 Cr
₹2 Cr₹2 Cr₹1 Cr₹67 L₹72 L₹68 L₹33 L₹34 L₹11 L-₹7 L₹61 L₹50 L₹15 L₹9 L₹20 L₹16 L₹19 L₹21 L₹23 L₹25 L₹27 L₹28 L₹26 L₹28 L₹27 L₹29 L₹27 L₹28 L₹30 L₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0
₹51 Cr₹58 Cr₹47 Cr₹73 Cr₹75 Cr₹78 Cr₹42 Cr₹51 Cr-₹15 Cr₹54 Cr₹20 Cr₹73 Cr₹71 Cr₹23 Cr₹39 Cr₹44 Cr₹27 Cr₹37 Cr₹16 Cr₹16 Cr₹14 Cr₹37 Cr₹28 Cr₹36 Cr₹26 Cr₹13 Cr₹35 Cr₹32 Cr₹34 Cr₹8 Cr₹41 Cr₹14 Cr₹9 Cr₹14 Cr-₹12 Cr₹34 Cr₹7 Cr-₹2 Cr₹21 Cr₹99 L₹15 Cr₹1 Cr₹9 Cr-₹7 Cr₹3 Cr₹38 Cr-₹13 Cr-₹28 Cr-₹18 Cr-₹3 Cr₹2 Cr-₹72 L₹2 Cr-₹19 Cr-₹18 Cr-₹21 Cr
₹38 Cr₹45 Cr₹33 Cr₹54 Cr₹56 Cr₹58 Cr₹31 Cr₹38 Cr-₹12 Cr₹39 Cr₹16 Cr₹52 Cr₹54 Cr₹17 Cr₹29 Cr₹33 Cr₹20 Cr₹28 Cr₹11 Cr₹12 Cr₹10 Cr₹27 Cr₹21 Cr₹26 Cr₹19 Cr₹10 Cr₹27 Cr₹14 Cr₹22 Cr₹10 Cr₹29 Cr₹9 Cr₹6 Cr₹3 Cr-₹10 Cr₹27 Cr₹6 Cr-₹10 Cr₹16 Cr₹80 L₹13 Cr₹56 L₹9 Cr-₹7 Cr₹3 Cr₹38 Cr-₹13 Cr-₹28 Cr-₹18 Cr-₹3 Cr₹2 Cr-₹1 Cr₹2 Cr-₹19 Cr-₹18 Cr-₹45 Cr

Share Price Live Stats

Open (₹)5,900.00
Volume (₹)656.00
High (₹)5,900.00
Upper Circuit7,053.00
Low (₹)5,835.00
Lower Circuit4,702.00
Prev Close5,877.50
52W High (₹)9,849.50
Price5,874.00
52W Low (₹)5,640.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)14717.50 Cr
Div. Yield (%)0.61
PE Ratio86.77
Debt to Equity0.00
Price to Book22.39
Book Value346.51
EPS (TTM)67.85
Face Value2.00
ROE (%)23.02

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
LAURUSLABSNSE
CIPLANSE
DRREDDYNSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
ASTRAZENNSE
LTP
1W Low
1W High
Market cap (₹)
1751.2-8.8 (-0.50%)
1743.10
1776.60
4,24,466Cr
9150-190 (-2.03%)
9060
9431.50
2,46,222Cr
4601-55.9 (-1.20%)
4551.80
4682
1,76,301Cr
1116.4-1.1 (-0.10%)
1107.30
1139.80
1,12,818Cr
2044.5+7.9 (0.39%)
2007.80
2069.20
1,10,823Cr
1316.5+15.5 (1.19%)
1300.20
1333.30
1,07,447Cr
1225.6+28.6 (2.39%)
1196.90
1250.70
1,03,471Cr
2340.5-28 (-1.18%)
2328.10
2426.80
97,850Cr
1680.9-12.1 (-0.71%)
1660.10
1715
96,836Cr
1936.6-19.9 (-1.02%)
1925.70
1964.90
89,629Cr
5874+37 (0.63%)
5790.50
5934.50
14,718Cr
Empty box

No content available